Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Public ClinicalTrials.gov record NCT06510504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Study identification
- NCT ID
- NCT06510504
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 370 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 5, 2024
- Primary completion
- Sep 10, 2025
- Completion
- Sep 18, 2025
- Last update posted
- May 18, 2026
2024 – 2025
United States locations
- U.S. sites
- 21
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AFFIRM-1 Study Site | Encino | California | 91316 | — |
| AFFIRM-1 Study Site | La Jolla | California | 92037 | — |
| AFFIRM-1 Study Site | Los Angeles | California | 90025 | — |
| AFFIRM-1 Study Site | Oceanside | California | 92056 | — |
| AFFIRM-1 Study Site | San Diego | California | 92103 | — |
| AFFIRM-1 Study Site | San Jose | California | 95124 | — |
| AFFIRM-1 Study Site | Sherman Oaks | California | 91403 | — |
| AFFIRM-1 Study Site | Temecula | California | 92591 | — |
| AFFIRM-1 Study Site | Jacksonville | Florida | 32256 | — |
| AFFIRM-1 Study Site | Lauderhill | Florida | 33319 | — |
| AFFIRM-1 Study Site | Miami Lakes | Florida | 33016 | — |
| AFFIRM-1 Study Site | Orlando | Florida | 32801 | — |
| AFFIRM-1 Study Site | Tampa | Florida | 33607 | — |
| AFFIRM-1 Study Site | Decatur | Georgia | 30030 | — |
| AFFIRM-1 Study Site | Boston | Massachusetts | 02114 | — |
| AFFIRM-1 Study Site | Boston | Massachusetts | 02131 | — |
| AFFIRM-1 Study Site | Princeton | New Jersey | 08540 | — |
| AFFIRM-1 Study Site | Brooklyn | New York | 11229 | — |
| AFFIRM-1 Study Site | Charlotte | North Carolina | 28211 | — |
| AFFIRM-1 Study Site | Media | Pennsylvania | 19063 | — |
| AFFIRM-1 Study Site | Austin | Texas | 78737 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06510504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2026 · Synced Sep 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06510504 live on ClinicalTrials.gov.